This metabolite has a PDE selectivity profile comparable to sildenafil and an in vitro potency for PDE5 around fifty% of the father or mother drug. Plasma concentrations of this metabolite are close to 40% of Individuals observed for sildenafil, so that the metabolite accounts for approximately 20% of sildenafil’s pharmacologic consequences.Tadal